Antiobsessional Effect of Risperidone Add-On Treatment in Serotonin Reuptake Inhibitor–Refractory Obsessive-Compulsive Disorder May Be Dose-Dependent

In their recent article, McDougle et al¹ concluded that patients with obsessive-compulsive disorder (OCD) refractory to serotonin reuptake inhibitor (SRI) monotherapy may respond to a mean ± SD low dose of risperidone (2.2 ± 0.7 mg) added to SRI treatment. However, the observed relationship between low doses of risperidone and its antiobsessional effect needs further evaluation.